Recombinant Staphylococcus epidermidis ATCC 12228 ARGC protein, His-tagged

• Cat.No.: ARGC-2973S
• Product Overview: Recombinant Staphylococcus epidermidis ATCC 12228 ARGC full length or partial length protein was expressed.

Specification

• Source: E. coli or Yeast
• Species: Staphylococcus
• Tag: His
• Form: Liquid or lyophilized powder
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method.
• Purity: > 80% by SDS-PAGE
• Notes: This item requires custom production and lead time is between 5-9 weeks. We can custom produce according to your specifications.
• Storage: Store it at +4 ºC for short term. For long term storage, store it at -20 ºC~-80 ºC.
• Storage buffer: PBS buffer

Gene Information

• Gene Name: argC N-acetyl-gamma-glutamyl-phosphate reductase [ Staphylococcus epidermidis ATCC 12228 ]
• Official Symbol: ARGC
• Synonyms: ARGC; N-acetyl-gamma-glutamyl-phosphate reductase
• Gene ID: 1057319
• UniProt ID: Q8CP35

Reviews

01/25/2022

Their extensive knowledge and expertise can help troubleshoot issues or provide guidance on experimental design, enabling you to overcome obstacles and achieve your research goals.

09/27/2021

This protein, manufactured with utmost precision, provides reliable and consistent results, ensuring the accuracy and reproducibility of your research findings.

05/20/2019

The manufacturer's commitment to customer satisfaction and their willingness to customize solutions based on specific experimental requirements is commendable.

08/08/2017

Choosing the ARGC protein from this manufacturer not only provides me with a superior product but also grants me access to unparalleled technical support.

05/20/2017

The manufacturer's extensive experience and expertise in the field of ARGC protein research make them a trusted partner.

02/21/2017

In protein electron microscopy structure analysis, the ARGC protein demonstrates outstanding performance.

12/23/2016

The manufacturer's commitment to customer satisfaction is unmatched.

05/08/2016

the ARGC protein's versatility allows it to be effectively employed in various experimental designs, further enhancing its suitability for diverse research needs.

Q&As

Are there any known interactions between ARGC and other proteins or molecules?

Yes, ARGC interacts with several other proteins and molecules in the pathway of creatine synthesis. It forms complexes with other enzymes, such as guanidinoacetate N-methyltransferase (GAMT) and S-adenosylmethionine decarboxylase (AdoMetDC), to carry out the sequential reactions involved in creatine production. It also interacts with S-adenosylmethionine (SAM), which serves as a methyl group donor in the biosynthesis process.

Can alterations in ARGC expression or activity have implications beyond creatine synthesis?

While the primary role of ARGC is in creatine synthesis, there is emerging evidence suggesting that alterations in ARGC expression or activity may have broader implications. Studies have linked dysregulation of creatine metabolism to neurodevelopmental disorders and neurodegenerative diseases. Understanding these potential implications and the underlying mechanisms is an active area of research.

What are the potential implications of ARGC dysfunction?

Dysfunction of the ARGC protein can result in impaired creatine synthesis, leading to a range of symptoms like developmental delays, intellectual disability, muscular weakness, and growth retardation. Prompt diagnosis and appropriate management can help mitigate the impact of these implications.

Are there any known drugs or compounds that target ARGC?

Currently, there are no approved drugs specifically targeting ARGC. However, some compounds have been investigated for their potential to modulate ARGC activity indirectly. For example, guanidinoacetate analogs or inhibitors have been studied as potential therapeutic agents to modulate creatine synthesis. Additionally, compounds that enhance creatine uptake, such as creatine transporters (CRT), may indirectly affect ARGC activity. Further research is needed to develop targeted drugs for ARGC-related conditions.

Is ARGC expression altered in any pathological conditions?

The expression of ARGC may be altered in certain pathological conditions, such as creatine synthesis disorders. Reduced ARGC expression or function can lead to a decrease in creatine synthesis, which can contribute to the symptoms observed in these conditions. Further studies are needed to explore additional pathological conditions that may involve altered ARGC expression.

Are there any diseases or conditions associated with mutations in the ARGC gene?

Yes, mutations in the ARGC gene can lead to certain disorders. One such disorder is guanidinoacetate methyltransferase (GAMT) deficiency, an autosomal recessive disorder characterized by a lack of creatine synthesis due to defects in the ARGC enzyme. This results in intellectual disability, seizures, speech and language impairments, and other neurological symptoms. Additionally, alterations in the ARGC gene may play a role in other conditions such as autism spectrum disorders and schizophrenia, although further research is needed to fully understand their contribution.

Can the ARGC protein be targeted for therapeutic purposes?

At present, there are no known specific therapies targeting the ARGC protein. However, approaches aimed at supplementing creatine levels, such as dietary interventions or creatine supplementation, may serve as potential treatment options for individuals with creatine synthesis disorders.

Are there any known mechanisms for post-translational modifications of ARGC?

Currently, there is limited knowledge about post-translational modifications of ARGC. However, it is speculated that phosphorylation, acetylation, or other modifications may potentially regulate the activity or stability of the protein. Future research may uncover additional post-translational modifications and their impact on ARGC function.

How is ARGC expression regulated at the genetic level?

The expression of ARGC is regulated by various genetic factors. Transcription factors can bind to specific regions of the ARGC gene, promoting or inhibiting its transcription. Epigenetic mechanisms, such as DNA methylation and histone modifications, can also influence the expression of ARGC by altering the accessibility of the gene to the transcriptional machinery.

How is the activity of ARGC regulated within cells?

The activity of ARGC is regulated through several mechanisms. One key regulatory mechanism is the availability of substrates and cofactors required for its catalytic function. This includes the availability of arginine, glycine, and S-adenosylmethionine (SAM), which are necessary for ARGC to produce guanidinoacetate. Additionally, the expression and activity of other enzymes in the creatine synthesis pathway, such as guanidinoacetate N-methyltransferase (GAMT) and S-adenosylmethionine decarboxylase (AdoMetDC), can also influence ARGC activity.

Are there any ongoing research efforts focused on ARGC and its functions?

Yes, ongoing research efforts are focused on further understanding ARGC and its functions. Scientists are studying the regulation of ARGC expression, post-translational modifications, and how it interacts with other molecules and proteins in the creatine synthesis pathway. Researchers are also investigating the implications of ARGC dysregulation in various diseases and exploring potential therapeutic strategies to target ARGC-related disorders. Continued research in these areas will contribute to a deeper understanding of ARGC's role in human health and may lead to the development of novel interventions in the future.

Are there any genetic variations or mutations in the ARGC gene associated with disease?

Yes, genetic variations in the ARGC gene have been associated with rare inborn errors of metabolism, such as arginine glycine amidinotransferase deficiency (AGAT deficiency). This condition impairs the ability to produce creatine, leading to developmental delays, intellectual disability, and muscle weakness.

Can ARGC activity be inhibited or enhanced by specific compounds?

Studies have identified certain compounds that can modulate ARGC activity. For example, certain analogs of arginine and glycine have been found to inhibit ARGC activity, potentially affecting creatine synthesis. Additionally, compounds or drugs that alter the availability of cofactors or modulators in the pathway may indirectly affect ARGC activity.

What are the potential implications of ARGC dysregulation in human health?

Dysregulation of ARGC and creatine metabolism has been associated with various human health conditions. Genetic disorders related to ARGC mutations, such as GAMT deficiency, can lead to intellectual disabilities and neurological symptoms. Additionally, abnormalities in the creatine system have been implicated in neurodevelopmental disorders including autism spectrum disorders and intellectual disabilities. Furthermore, disrupted creatine metabolism is being investigated in neurodegenerative diseases such as Parkinson's and Alzheimer's, highlighting the potential broader implications of ARGC dysregulation in human health.

Are there any therapeutic strategies being explored to target ARGC-related disorders?

Currently, there are no specific therapies designed to directly target ARGC-related disorders. However, research is ongoing to investigate potential strategies such as gene therapy, small molecule interventions modulating the creatine pathway, or approaches to enhance creatine uptake in affected cells. These endeavors aim to develop targeted therapies for individuals with ARGC-related disorders.